Findings

What do systematic reviews say?

17 questions · 17 findings · 10 reviews · Heart

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 5 · 29.4%Low 7 · 41.2%Moderate 4 · 23.5%High 1 · 5.9%

PAP therapy vs usual care

All‐cause mortality · heart failure associated with central sleep apnoea

It is very uncertain whether PAP therapy changes all‐cause mortality compared with usual care (very low certainty).

1 finding from 1 review

Positive airway pressure therapy for the treatment of central sleep apnoea associated with heart failure 2019 · Cochrane Headline outcomes only
RR 0.81 [0.54, 1.21]
6 studies · 1804 participants
Very low

Stem cell therapy vs peripheral therapy with granulocyte colony‐stimulating factor

All‐cause mortality · DCM (non‐ischaemic)

It is very uncertain whether stem cell therapy (any type) changes all‐cause mortality compared with peripheral therapy with granulocyte colony‐stimulating factor (very low certainty).

1 finding from 1 review

Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
RR 0.46 [0.16, 1.31]
3 studies · 195 participants
Very low

Stem cell therapy vs control

All‐cause mortality · DCM (non‐ischaemic)

It is very uncertain whether stem cell therapy changes all‐cause mortality compared with control (very low certainty).

1 finding from 1 review

Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
RR 0.84 [0.54, 1.31]
7 studies · 361 participants
Very low

Ranolazine (monotherapy) vs placebo

All‐cause mortality · patients with stable angina pectoris

Ranolazine (monotherapy) showed no clear difference in all‐cause mortality compared with placebo (low certainty).

1 finding from 1 review

Ranolazine for stable angina pectoris 2017 · Cochrane Headline outcomes only
RR 1 [0.81, 1.25]
3 studies · 6249 participants
Low

Ranolazine (add‐on therapy) vs placebo

All‐cause mortality · patients with stable angina pectoris

Ranolazine (add‐on therapy) showed no clear difference in all‐cause mortality compared with placebo (low certainty).

1 finding from 1 review

Ranolazine for stable angina pectoris 2017 · Cochrane Headline outcomes only
RR 0.83 [0.26, 2.71]
3 studies · 2053 participants
Low

ICD plus optimal medical therapy vs optimal medical therapy alone

All‐cause mortality (HR) ‐ main analysisa 16.5 to 67.6 months · DCM (non‐ischaemic)

ICD plus optimal medical therapy leads to lower all‐cause mortality (HR) ‐ main analysisa 16.5 to 67.6 months compared with optimal medical therapy alone (high certainty).

1 finding from 1 review

Implantable cardiac defibrillators for people with non‐ischaemic cardiomyopathy 2018 · Cochrane Headline outcomes only
HR 0.78 [0.66, 0.92]
6 studies · 3128 participants
High

Interrupted vs uninterrupted anticoagulation therapy

All‐cause mortality · adults with arrhythmias undergoing catheter ablation

Interrupted showed no clear difference in all‐cause mortality compared with uninterrupted anticoagulation therapy (low certainty).

1 finding from 1 review

Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias 2021 · Cochrane Headline outcomes only
RR 0.34 [0.01, 8.21]
1 study · 442 participants
Low

Implantable cardioverter defibrillators vs beta‐blocker

All‐cause mortality · people with cardiac channelopathies

Implantable cardioverter defibrillators may leads to lower all‐cause mortality compared with β‐blocker therapy (low certainty).

1 finding from 1 review

Implantable defibrillators versus medical therapy for cardiac channelopathies 2015 · Cochrane Headline outcomes only
RR 0.11 [0.01, 0.83]
2 studies · 86 participants
Low

Coenzyme Q10 vs placebo or conventional therapy

All‐cause mortality · patients with heart failure

Coenzyme Q10 probably leads to lower all‐cause mortality compared with placebo or conventional therapy (moderate certainty).

1 finding from 1 review

Coenzyme Q10 for heart failure 2021 · Cochrane Headline outcomes only
RR 0.58 [0.35, 0.95]
1 study · 420 participants
Moderate

self‐management of oral anticoagulation vs usual care

All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment

self‐management of oral anticoagulation probably leads to lower all‐cause mortality compared with standard care (moderate certainty).

1 finding from 1 review

Self‐monitoring and self‐management of oral anticoagulation 2016 · Cochrane Headline outcomes only
RR 0.55 [0.36, 0.84]
8 studies · 3058 participants
Moderate

Self‐monitoring or self‐management of oral anticoagulation vs usual care

All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment

Self‐monitoring or self‐management of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).

1 finding from 1 review

Self‐monitoring and self‐management of oral anticoagulation 2016 · Cochrane Headline outcomes only
RR 0.85 [0.71, 1.01]
11 studies · 6358 participants
Moderate

Self‐monitoring of oral anticoagulation vs usual care

All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment

Self‐monitoring of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).

1 finding from 1 review

Self‐monitoring and self‐management of oral anticoagulation 2016 · Cochrane Headline outcomes only
RR 0.94 [0.78, 1.15]
3 studies · 3300 participants
Moderate

Interrupted vs uninterrupted anticoagulation therapy

Composite endpoint of thromboembolic events (stroke or systemic embolism), major bleeding events, and all‐cause mortality · adults with arrhythmias undergoing catheter ablation

Interrupted may leads to lower composite endpoint of thromboembolic events (stroke or systemic… compared with uninterrupted anticoagulation therapy (low certainty).

1 finding from 1 review

Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias 2021 · Cochrane Headline outcomes only
RR 0.23 [0.07, 0.81]
1 study · 442 participants
Low

Intervention not reported

All‐cause mortality Median · adults older than 18 years, with no restriction regarding presence of ASCVD; participants generally had elevated risk of ASCVD (as…

The intervention showed no clear difference in all‐cause mortality Median (low certainty).

1 finding from 1 review

Fixed‐dose combination therapy for the prevention of atherosclerotic cardiovascular diseases 2017 · Cochrane Headline outcomes only
RR 1.1 [0.64, 1.89]
5 studies · 5300 participants
Low

Oxygen vs air

All‐cause mortality in hospital for participants with AMI · patients with acute myocardial infarction

It is very uncertain whether oxygen changes all‐cause mortality in hospital for participants with AMI compared with air (very low certainty).

1 finding from 1 review

Oxygen therapy for acute myocardial infarction 2016 · Cochrane Headline outcomes only
RR 1.02 [0.52, 1.98]
4 studies · 871 participants
Very low

Oxygen vs air

All‐cause mortality in hospital for all participants (including those without confirmed AMI) · patients with acute myocardial infarction

It is very uncertain whether oxygen changes all‐cause mortality in hospital for all participants (including… compared with air (very low certainty).

1 finding from 1 review

Oxygen therapy for acute myocardial infarction 2016 · Cochrane Headline outcomes only
RR 0.99 [0.5, 1.95]
4 studies · 1123 participants
Very low

Oxygen vs air

All‐cause mortality in hospital for all participants (including those without confirmed AMI) trials done in the revascularisation era · patients with acute myocardial infarction

Oxygen showed no clear difference in all‐cause mortality in hospital for all participants (including… compared with air (low certainty).

1 finding from 1 review

Oxygen therapy for acute myocardial infarction 2016 · Cochrane Headline outcomes only
RR 0.58 [0.24, 1.39]
3 studies · 923 participants
Low